Combining Chk1/2 inhibition with radiation in head and neck cancer

Medicine and Dentistry

• Head and Neck Cancer 100%
• DNA Damage Response 50%
• Patient 33%
• Clinical Trial 33%
• Therapeutics 33%
• Therapeutic Procedure 16%
• In Vitro 16%
• Clinical Study 16%
• DNA Damage 16%
• Neck 16%
• DNA Repair 16%
• Tumor Progression 16%
• Tumor Cell 16%
• Survival Rate 16%
• Epidermal Growth Factor Receptor 16%
• Ionizing Radiation 16%
• Cell Cycle Checkpoint 16%
• First-Line Chemotherapy 16%
• DNA 16%
• Cisplatin 16%
• Cetuximab 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Head and Neck Cancer 100%
• DNA 66%
• Clinical Trial 33%
• Cisplatin 16%
• First-Line Chemotherapy 16%
• Preclinical Study 16%
• Tumor Growth 16%
• Ionizing Radiation 16%
• Survival Rate 16%
• Neoplasm 16%
• Cetuximab 16%
• Epidermal Growth Factor Receptor 16%
• Gene Delivery 16%